|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Allergan
|
|
gptkbp:acquisitionYear
|
2020
|
|
gptkbp:CEO
|
gptkb:Richard_A._Gonzalez
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusArea
|
aesthetics
immunology
neuroscience
oncology
women's health
gastroenterology
virology
eye care
|
|
gptkbp:Fortune500Rank
|
~63 (2023)
|
|
gptkbp:founded
|
2013
|
|
gptkbp:headquartersLocation
|
gptkb:North_Chicago,_Illinois,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AbbVie (2013)
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:marketCap
|
over $250 billion (2024)
|
|
gptkbp:netIncome
|
$4.87 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Humira
gptkb:Imbruvica
gptkb:Rinvoq
gptkb:Skyrizi
|
|
gptkbp:numberOfEmployees
|
~50,000 (2023)
|
|
gptkbp:originatedIn
|
gptkb:Abbott_Laboratories
|
|
gptkbp:parentCompany
|
gptkb:Abbott_Laboratories_(prior_to_2013_spin-off)
|
|
gptkbp:publiclyTraded
|
gptkb:NYSE
|
|
gptkbp:revenue
|
$58.05 billion (2023)
|
|
gptkbp:S&P500Component
|
true
|
|
gptkbp:stockSymbol
|
gptkb:NYSE
gptkb:ABBV
|
|
gptkbp:website
|
https://www.abbvie.com/
|
|
gptkbp:bfsParent
|
gptkb:Abbott_Laboratories
|
|
gptkbp:bfsLayer
|
6
|